N. Ireland Cancer Registry Implications of Research for Services

NICR Lead Author Helen Coleman

(Office use only)	
	Paper ID
	(Office use only)
	Date Submitted to NICR Steering Group Click here to enter a date. (Office use only)
Paper Title	The Impact of the COVID-19 Pandemic on Barrett's
	Esophagus and Esophago-gastric Cancer
Authors	Richard C. Turkington, Anita Lavery, David Donnelly,
	Victoria Cairnduff, Damian T.McManus, Helen G. Coleman
Journal	Gastroenterology
DOI	https://doi.org/10.1053/j.gastro.2021.01.208
Funders	Grant Support:
	Cancer Research UK (C50880/A29831), (C37703/A25820),
	Cancer Focus NI
	OGCancer NI Wellcome Trust and Health Research Board
	(203930/B/16/Z)
	(203930/B/10/2) Public Health Agency, Northern Ireland.
Full paper available online	YES NO NOT YET
Tan paper available online	
Conclusion	We investigated how the COVID-19 pandemic has affected
	the diagnosis of oesophageal and stomach cancer and
	Barrett's oesophagus. Analysing data from the Northern
	Ireland Cancer Registry, we estimated the number of
	patients who had been diagnosed with these conditions
	across Northern Ireland between March and September
	2020, and compared this with data from 2017-2019.
	Me formal that diamages of according and atomage.
	We found that diagnoses of oesophageal and stomach
	cancer fell by 26.6%; meaning that 53 fewer patients than expected were diagnosed during the first six months of the
	pandemic. For Barrett's oesophagus, diagnoses fell by
	59.3% which represents 236 fewer Barrett's cases than
	expected
	· ·
What this means for the service	This study is the first to show the impact of COVID-19 on the
	pre-cancerous condition, Barrett's oesophagus.
	There will be missed opportunities for prevention of cancers
	due to this sharp decline in Barrett's oesophagus diagnoses.

Coupled with the drop in expected numbers of oesophageal and stomach cancer diagnoses, we are very concerned that patients will present later with more advanced disease and have poorer survival outcomes as a result. It is vital that we protect and reinstate our cancer diagnostic services, such as endoscopy, to help minimise the impact of the pandemic on cancer patients